Christopher W. Ryan, M.D.

Head Shot of Christopher Ryan
click here
503 494-6594


Dr. Ryan is a clinical researcher whose work focuses on testing new agents for renal carcinoma and sarcomas. He is particularly interested in clinical trial design and novel endpoints. He is currently studying the utility of dynamic contrast enhanced MRI data as a biomarker for activity of novel agents in the treatment of soft tissue sarcomas. His clinical practice is centered around an active trial portfolio.

Selected Publications

"Skeletal response to resistance and impact training in prostate cancer survivors," Medicine and Science in Sports and Exercise (Vol: 46, Issue: 8, Page 1482-1488) - 2014

"A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma," Cancer Biology and Therapy (Vol: 14, Issue: 2, Page 95-99) - 2013

"A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma," Investigational New Drugs (Vol: 31, Issue: 1, Page 145-151) - 2013

"MDM2 amplification and PI3KCA mutation in a case of sclerosing rhabdomyosarcoma," Sarcoma (Vol: 2013, ) - 2013

"Overcoming autopsy barriers in pediatric cancer research," Pediatric Blood and Cancer (Vol: 60, Issue: 2, Page 204-209) - 2013


OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


  Email Christopher Ryan

503 494-6594

Memberships & Associations

  • American Society of Clinical Oncology
  • Children’s Oncology Group
  • Connective Tissue Oncology Society
  • Oregon Medical Association
  • Southwest Oncology Group